PTGFR
Prostaglandin F2-alpha receptor
As of the edition of 20 October 2026, PTGFR (prostaglandin F2-alpha receptor, UniProt P43088) has 9 drugs tested at it and 18 companies on the list, 0 on route A and 10 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P43088
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 8
- Disease areas
- Eye; Skin and connective tissue; Heart and blood vessels; Inherited and neonatal; Hormones; Immune system; Pregnancy and women's health; Urinary and reproductive
- Registered trials of its drugs
- 294
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 7 |
| Went quiet | 1 |
| Status not established | 1 |
| Total | 9 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Bimatoprost | Marketed | Phase 4 | Ends 2031 |
| Latanoprost | Marketed | Phase 4 | none listed |
| Travoprost | Marketed | Phase 4 | none listed |
| Tafluprost | Marketed | Phase 4 | none listed |
| Latanoprostene bunod | Marketed | Phase 4 | Ends 2029 |
| Carboprost | Marketed | Phase 1 | none listed |
| AL-12182 | Went quiet | Phase 2 | none listed |
| Dinoprost | Marketed | No phase stated | none listed |
| Ebopiprant | Status not established | Phase 2 | none listed |
9 of 9 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route B | 10 |
| Engaged | 6 |
| Undetermined | 2 |
| Total on the list | 18 |
The other 15 companies at PTGFR
In the product18 companies in all; 15 are not named here, and no score is.
See the 18 companies at PTGFR, ranked, with the facts behind eachRequest access. Nothing is shown until you do.